| Literature DB >> 32582691 |
Xueke Zhou1,2, Yimei Hong1, Hao Zhang3, Xin Li1,2.
Abstract
Over the past decades, mesenchymal stem cell (MSC)-based therapy has been intensively investigated and shown promising results in the treatment of various diseases due to their easy isolation, multiple lineage differentiation potential and immunomodulatory effects. To date, hundreds of phase I and II clinical trials using MSCs have been completed and many are ongoing. Accumulating evidence has shown that transplanted allogeneic MSCs lose their beneficial effects due to immunorejection. Nevertheless, the function of autologous MSCs is adversely affected by age, a process termed senescence, thus limiting their therapeutic potential. Despite great advances in knowledge, the potential mechanisms underlying MSC senescence are not entirely clear. Understanding the molecular mechanisms that contribute to MSC senescence is crucial when exploring novel strategies to rejuvenate senescent MSCs. In this review, we aim to provide an overview of the biological features of senescent MSCs and the recent progress made regarding the underlying mechanisms including epigenetic changes, autophagy, mitochondrial dysfunction and telomere shortening. We also summarize the current approaches to rejuvenate senescent MSCs including gene modification and pretreatment strategies. Collectively, rejuvenation of senescent MSCs is a promising strategy to enhance the efficacy of autologous MSC-based therapy, especially in elderly patients.Entities:
Keywords: autophagy; mesenchymal stem cells; mitochondrial; rejuvenation; senescence; telomere
Year: 2020 PMID: 32582691 PMCID: PMC7283395 DOI: 10.3389/fcell.2020.00364
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Different types of MSCs senescence.
FIGURE 2Mechanisms of MSC senescence and their rejuvenation.
Summary of published data on the application of microRNA retraining of MSCs from senescence.
| miR-217 overexpression | BMMSCs | Targeted to DKK1 | Osteogenic differentiation | |
| Downregulation of miR-196 | BMMSCs | Targeted to HOXB7 | An improved osteogenesis | |
| Downregulation of miR−195 | BMMSCs | Targeted to Tert | Reactivating telomerase | |
| Downregulation of miR-34a | BMMSCs | Targets SIRT1 | Activation of the SIRT1/FOXO3a pathway, improve mitochondrial function | |
| Downregulation of miR-29b-3p | BMMSCs | Targets SIRT1 | Regulates aging-associated insulin resistance | |
| Downregulation of miR-29c-3p | BMMSCs | Targets CNOT6 | Affected the p53–p21 and the p16–pRB pathways | |
| Downregulation of miR-27b | Ad-MSCs | Unknown | Downregulated p16 and MARP3 genes, increased MSC migration | |
| miR-211 overexpression | BMMSCs | Targets STAT5A | Enhance migration ability | |
| Downregulation of miR-141-3p | UCB-MSCs | Targets ZMPSTE24 | Suppression of an abnormal nuclear phenotype in the HDAC-inhibitor-treated cells | |
| Upregulation of miR-10b | Ad-MSCs | Targets SMAD2 | A balancing osteogenic and adipogenic differentiation | |
| Upregulation of miR-10a | BMMSCs | Targets KLF4 | Promoted implanted stem cell survival | |
| Downregulation of miR-1292 | Ad-MSCs | Targets FZD4 | Delay senescence and enhance bone formation | |
| Downregulation of miR-31 | Ad-MSCs | Targets Frizzled-3 | Osteogenesis |